Essex Investment Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Essex Investment Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,294	Closed	-$306K	–	363
2014 Q3	$306K	Buy	1,294 +446	+53%	+$114K	0.05%	289
2014 Q2	$201K	Hold	848	–	–	0.03%	333
2014 Q1	$280K	Sell	848 -7,196	-89%	-$2.43M	0.04%	305
2013 Q4	$549K	Buy	8,044 +3,491	+77%	+$202K	0.08%	258
2013 Q3	$314K	Sell	4,553 -4,391	-49%	-$217K	0.05%	303
2013 Q2	$401K	Buy	+8,944	New	+$306K	0.07%	238

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Essex Investment Management's ICPT Position: Q4 2014 in Review

Essex Investment Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2014, closing a stake of 1,294 shares — an estimated $306K sold.

Essex Investment Management first reported a position in ICPT in Q2 2013 and held it in 6 quarters. The position peaked at $549K in Q4 2013. 169 funds tracked by Wall St. Rank hold ICPT as of Q4 2014.

Essex Investment Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
Essex Investment Management sold 1,294 Intercept Pharmaceuticals, Inc. shares in Q4 2014, an estimated $306K.
Essex Investment Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 6 quarters.
Essex Investment Management's Intercept Pharmaceuticals, Inc. position peaked at $549K in Q4 2013.
169 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2014.

Based on Essex Investment Management's 13F filing for Q4 2014, filed 27 Jan 2015.